(-)-(3S,4R)-2,2-Dimethyl-4-(4-methylamino-1,1-dioxo-[1,2,5]-thiadiazol-3-ylamino)-6-trifluoromethoxy-chroman-3-ol | 149520-78-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (-)-(3S,4R)-2,2-Dimethyl-4-(4-methylamino-1,1-dioxo-[1,2,5]-thiadiazol-3-ylamino)-6-trifluoromethoxy-chroman-3-ol
• 英文别名: (3S,4R)-2,2-dimethyl-4-[(4-methylimino-1,1-dioxo-1,2,5-thiadiazolidin-3-ylidene)amino]-6-(trifluoromethoxy)-3,4-dihydrochromen-3-ol
• CAS: 149520-78-5
• 化学式: C₁₅H₁₇F₃N₄O₅S
• 分子量: 422.385
• InChiKey: WWUJLTVPGJZXRT-MNOVXSKESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  130
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  (-)-(3S,4R)-4-(4-ethoxy-1,1-dioxo-[1,2,5]thiadiazol-3-ylamino)-2,2-dimethyl-6-trifluoromethoxy-chroman-3-ol 在 甲胺 作用下， 以 乙腈 为溶剂， 以0.17 g (88%)的产率得到(-)-(3S,4R)-2,2-Dimethyl-4-(4-methylamino-1,1-dioxo-[1,2,5]-thiadiazol-3-ylamino)-6-trifluoromethoxy-chroman-3-ol
  参考文献：
  名称：

  Thiadiazolyl-amino derivatives of benzopyrans and indanes

  摘要：

  分子式为：##STR1## 其中R.sub.1和R.sub.2，独立于彼此，选择自以下：C.sub.1-6全氟烷氧基，C.sub.1-6全氟烷基，C.sub.1-6烷基，C.sub.1-6烷氧基，羟基，C.sub.2-6烷氧羰基，硝基，氰基，卤素基，C.sub.1-6烷基磺酰胺基，C.sub.1-6全氟烷基磺酰胺基，氨基，C.sub.2-6酰胺基，C.sub.2-6全氟烷基酰胺基，C.sub.1-12单烷基或双烷基氨基，C.sub.1-6烷基磺酰基，C.sub.6-12芳基磺酰基，羧基，C.sub.2-12单烷基或双烷基氨基甲酰基，或氢; a和b一起形成--O--连接或直接键; R.sub.3和R.sub.4，独立于彼此，当a和b形成--O--连接时为C.sub.1-6烷基，当a和b形成直接键时为H或C.sub.1-6烷基; R.sub.5为氢，羟基，C.sub.2-6烷基氧羰基，C.sub.7-12芳基氧基，氨基甲酰氧基，甲氧基羰酸酯基，单烷基或双C.sub.2-12烷基氨基甲酰氧基，R.sub.6为氢，或R.sub.5和R.sub.6一起是一个键; R.sub.7为氢，C.sub.1-6烷基，C.sub.1-6烷基羧酰基或C.sub.16烷基磺酰基; X选择自以下：--NR.sub.8 R.sub.9，其中R.sub.8和R.sub.9，独立于彼此，是氢，C.sub.1-6烷基，C.sub.2-6烷基羧酰基，C.sub.7-12芳基烷基，噻吩甲基，吡啶甲基，哌嗪基甲基或嘧啶甲基，或R.sub.8和R.sub.9一起是3-10个碳原子的聚亚甲基，或R.sub.8和R.sub.9与它们附着的氮原子一起形成哌嗪，吗啉，吡咯烷，吡咯烷酮，咪唑，咪唑酮，哌啶或哌啶酮环结构; 或--OR.sub.10，其中R.sub.10为氢，C.sub.1-6烷基或C.sub.2-6烷基羧酰基; n是0-2的整数; 或其药学上可接受的盐，是有用的降压、K通道激活剂。

  公开号：

  US05206252A1

文献信息

• Thiadiazolyl-amino derivatives of benzopyrans and indanes
  申请人：American Home Products Corporation

  公开号：US05206252A1

  公开（公告）日：1993-04-27

  The compounds of the formula: ##STR1## wherein R.sub.1 and R.sub.2, independent from each other, are selected from the following: C.sub.1-6 perfluoroalkoxy, C.sub.1-6 perfluoroalkyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxyl, C.sub.2-6 alkoxycarbonyl, nitro, cyano, halogeno, C.sub.1-6 alkylsulfonamido, C.sub.1-6 perfluoroalkylsulfonamido, amino, C.sub.2-6 alkanoylamino, C.sub.2-6 perfluoroalkanoylamino, C.sub.1-12 mono- or di-alkylamino, C.sub.1-6 alkylsulfonyl, C.sub.6-12 arylsulfonyl, carboxyl, C.sub.2-12 mono- or di-alkylcarbamoyl, or hydrogen; a and b together form an --O-- linkage or a direct bond; R.sub.3 and R.sub.4, independent from each other, are C.sub.1-6 alkyl when a and b form an --O-- linkage or, H or C.sub.1-6 alkyl when a and b form a direct bond; either R.sub.5 is hydrogen, hydroxyl, C.sub.2-6 alkanoyloxy, C.sub.7-12 aroyloxy, carbamoyloxy, formyloxy, C.sub.2-6 alkoxycarbonyloxy, mono or di C.sub.2-12 alkylcarbamoyloxy, and R.sub.6 is hydrogen, or R.sub.5 and R.sub.6 together are a bond; R.sub.7 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkanocarbonyl, or C.sub.16 alkanosulfonyl; X is selected from the following: --NR.sub.8 R.sub.9, wherein R.sub.8 and R.sub.9, independent from each other are hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkylcarbonyl, C.sub.7-12 arylalkyl, thienylmethyl, pyridinylmethyl, piperazinylmethyl, or pyrimidinylmethyl, or R.sub.8 and R.sub.9 taken together are polymethylene of 3-10 carbon atoms or R.sub.8 and R.sub.9 taken with the nitrogen atom to which they are attached complete a piperazine, morpholine, pyrroline, pyrrolidinone, imidazole, imidazolone, piperidine or piperidinone ring structure; or --OR.sub.10, wherein R.sub.10 is hydrogen, C.sub.1-6 alkyl or C.sub.2-6 alkylcarbonyl; and n is an integer from 0-2; or a pharmaceutically acceptable salt thereof, are useful antihypertensive, K channel activators.

  分子式为：##STR1## 其中R.sub.1和R.sub.2，独立于彼此，选择自以下：C.sub.1-6全氟烷氧基，C.sub.1-6全氟烷基，C.sub.1-6烷基，C.sub.1-6烷氧基，羟基，C.sub.2-6烷氧羰基，硝基，氰基，卤素基，C.sub.1-6烷基磺酰胺基，C.sub.1-6全氟烷基磺酰胺基，氨基，C.sub.2-6酰胺基，C.sub.2-6全氟烷基酰胺基，C.sub.1-12单烷基或双烷基氨基，C.sub.1-6烷基磺酰基，C.sub.6-12芳基磺酰基，羧基，C.sub.2-12单烷基或双烷基氨基甲酰基，或氢; a和b一起形成--O--连接或直接键; R.sub.3和R.sub.4，独立于彼此，当a和b形成--O--连接时为C.sub.1-6烷基，当a和b形成直接键时为H或C.sub.1-6烷基; R.sub.5为氢，羟基，C.sub.2-6烷基氧羰基，C.sub.7-12芳基氧基，氨基甲酰氧基，甲氧基羰酸酯基，单烷基或双C.sub.2-12烷基氨基甲酰氧基，R.sub.6为氢，或R.sub.5和R.sub.6一起是一个键; R.sub.7为氢，C.sub.1-6烷基，C.sub.1-6烷基羧酰基或C.sub.16烷基磺酰基; X选择自以下：--NR.sub.8 R.sub.9，其中R.sub.8和R.sub.9，独立于彼此，是氢，C.sub.1-6烷基，C.sub.2-6烷基羧酰基，C.sub.7-12芳基烷基，噻吩甲基，吡啶甲基，哌嗪基甲基或嘧啶甲基，或R.sub.8和R.sub.9一起是3-10个碳原子的聚亚甲基，或R.sub.8和R.sub.9与它们附着的氮原子一起形成哌嗪，吗啉，吡咯烷，吡咯烷酮，咪唑，咪唑酮，哌啶或哌啶酮环结构; 或--OR.sub.10，其中R.sub.10为氢，C.sub.1-6烷基或C.sub.2-6烷基羧酰基; n是0-2的整数; 或其药学上可接受的盐，是有用的降压、K通道激活剂。